Search

everythinglearnresearchcommunity

for

Search:↓

People are discussing ordering pyrilutamide for hair loss treatment in the US. The treatment is from Kintor's subsidiary company and is available on Amazon.

The conversation is about the difficulty in obtaining GT20029, a hair loss treatment, due to patent issues and the need to resort to group buys or Chinese labs for acquisition. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

The conversation discusses hair loss treatments, focusing on Tsuji's hair cloning and Shiseido's RCH-01, with skepticism about their effectiveness on humans. It compares these to PRP, noting PRP's higher efficacy in studies.

Hair loss treatments discussed include promising Pyr available online and Verteporfin dosing after FUE for follicle regeneration, but no updates on SCUBE3.

Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.

User experienced hair regrowth after eliminating scalp itch with RU58841. Others discussed itch and hair loss connection, and effectiveness of combining RU58841 with 5AR inhibitors.

Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.

The user is considering adding Stemoxydine to their hair loss regimen, as they already use topical finasteride with rosemary and cannot use Minoxidil. They are seeking feedback on Stemoxydine and Alphatradiol, and another user mentions 2-deoxy-d-ribose as a potential option.

A user received KX-826 instead of RU58841 and is confused about their order. They are asking if others have experienced similar issues.

The user is experiencing hair regrowth and increased hair thickness after using supplements like biotin, zinc, selenium, and a complex with various natural ingredients, along with topical caffeine. They are considering using topical minoxidil and mesotherapy in the future.

The conversation discusses Kevin's accurate information on hair loss treatments and highlights Dr. Bloxham's ongoing work with Verteporfin on FUT scars, suggesting people follow Dr. Bloxham's YouTube for updates. It also thanks Haicafe and Melvin from the hair restoration network forum for their contributions.

Hair loss discussion includes treatments like hinoki tree oil and procyanidin b2. Experiences and effectiveness of these treatments are shared.

RU58841 not working for hair loss after 10 months. Concerns about purity of experimental drugs.

RU58841 is a strong non-steroidal antiandrogen for hair loss but may cause cardiovascular issues in some users. Alternatives like Pyrilutamide and Breezula are suggested due to better safety profiles and lower systemic risks.

Hair loss itch is caused by DHT attacking follicles and stimulating nerves. Finasteride users who respond well don't experience this itch.

A 17-year-old is concerned about potential hair loss due to maternal genetics and wonders if treatments like Minoxidil, Finasteride, or RU58841 will be effective. They hope their paternal genetics will help prevent hair loss or make treatments more effective.

UCLA's PP405 shows promise in reactivating dormant hair follicles for hair loss treatment but is still in clinical trials. Minoxidil and finasteride remain common treatments until PP405 becomes available.

The user is seeking advice on a hair loss treatment called Ell Cranell, which contains Alfatradiol. Another user shared information from a study stating that Alfatradiol only slows down or stabilizes hair loss, but does not increase hair density or thickness.

RU58841 for hair loss, with users discussing sources, effectiveness, and side effects. Some users report side effects and question the long-term safety of RU58841.

RU58841 showed promise for treating androgenic alopecia but research was halted due to financial and organizational changes. There were no significant safety concerns reported in human trials.

Kintor's Pyrilutamide results for hair loss treatment will be released soon. The treatment may replace current treatments like finasteride and minoxidil without systemic side effects.

KX826 is considered a legitimate option for those who cannot use finasteride or dutasteride, but many users report it as ineffective compared to RU58841. RU58841 is favored by some due to anecdotal evidence of effectiveness, despite the lack of published clinical data.

Sulforaphane, found in broccoli sprouts, promotes hair growth by degrading DHT. Users discuss its potential benefits and joke about unconventional application methods.

The conversation discusses disappointment with the hair loss treatment KX-826 but notes that the company Kintor is still focused on developing and commercializing it, as stated in their 2023 annual report. The user questions the effectiveness of KX-826 in comparison to minoxidil's role in improving hair thickness and appearance.

Rob Holding's hair transplant, which looks great despite the edited image of it; many respondents discussed their opinions on the hairstyle, while others suggested treatment options like Minoxidil and Finasteride.

The conversation is about finding a cheaper source for RU58841, with a suggestion to use Chemyo. One user suggests that RU58841 may not be necessary.

The conversation discusses potential advancements in two hair loss drugs, KX-826 and GT20029, and the interest in whether transitioning from oral finasteride to these drugs would maintain hair growth. One reply expresses skepticism about the compounds' representation.

The conversation is about choosing between gray market Pyrilutamide and the official Kintor version for hair loss treatment. Users share mixed experiences, with some finding both versions effective and others not seeing results.

Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.

Male pattern baldness (MPB) may be influenced by androgen receptors in scalp hair follicles and potentially poor blood flow. Transplanted hair is not immune to DHT, and factors like inflammation and scalp tension might also contribute to hair loss.